- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Gregory Vidal, MD, PhD | Authors
Key Takeaways & Clinical Implications
November 03, 2022
A commentary on key takeaways from TROPiCS-02, remaining questions and unmet needs in the field, and the clinical implications of using SG and other Trop-2–directed ADCs in patients with HR+/HER2- mBC.
TROPiCS-02: PFS Subgroup Analysis, Summary of Response Rates, and AEs
November 03, 2022
Drs Dietrich, Tolaney, and Vidal comment on PFS subgroup analyses, response rates, and common adverse events (AEs) observed in the TROPiCS-02 trial.
PFS and OS Data from TROPiCS-02
October 27, 2022
Experts discuss progression-free survival (PFS) and overall survival (OS) data from the TROPiCS-02 trial on SG versus treatment of physician’s choice.
TROPiCS-02 Study Overview and Patient Baseline Characteristics
October 27, 2022
Dr Tolaney discusses the TROPiCS-02 study design and comments on the key baseline characteristics of the patients with HR+/HER2- mBC who were enrolled in the trial.
The Role of Trop-2 in mBC and the Rationale for Use of Trop-2–directed ADCs
October 20, 2022
Dr Vidal elaborates on the role of trophoblast cell-surface antigen 2 (Trop-2) in metastatic breast cancer and discusses the rationale for using Trop-2–directed antibody-drug conjugates (ADCs), including sacituzumab govitecan (SG), in patients with the disease.
Article Introduction and HR+/HER2 mBC Background
October 20, 2022
Sara Tolaney, MD, MPH introduces the 2022 Journal of Clinical Oncology preprint publication, “Sacituzumab Govitecan in Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer” and invites Martin Dietrich, MD, PhD and Gregory Vidal, MD, PhD to comment on the typical patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2-) metastatic breast cancer (mBC) who they see in their clinical practice.